WO2025202941 - NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY
National phase entry is expected:
Publication Number
WO/2025/202941
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053216
International Filing Date
26.03.2025
Title **
[English]
NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHY
[French]
FACTEUR DE CROISSANCE NERVEUSE ET SES PROCÉDÉS D'UTILISATION POUR DES HANDICAPS NEURODÉVELOPPEMENTAUX ASSOCIÉS À L'ENCÉPHALOPATHIE HYPOXIQUE ISCHÉMIQUE NÉONATALE
Applicants **
DOMPE' FARMACEUTICI S.P.A.
Inventors
ARAMINI, Andrea
BRANDOLINI, Laura
BOCCELLA, Serena
NOVELLI, Rubina
Priority Data
24167048.8
27.03.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4586 | |
| EPO | Filing, Examination, Granting | 76180 | |
| Japan | Filing, Examination, Granting | 4446 | |
| South Korea | Filing, Examination, Granting | 6558 | |
| USA | Filing, Examination, Granting | 18340 |
Total:
110,110
Contact Us
Abstract[English]
The present disclosure relates to nerve growth factor (NGF) for use in the prevention or treatment of neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy in a subject, wherein the NGF is administered intranasally to the subject.[French]
La présente divulgation concerne le facteur de croissance nerveuse (NGF) destiné à être utilisé dans la prévention ou le traitement de troubles neurodéveloppementaux associés à l'encéphalopathie hypoxique ischémique néonatale chez un sujet, le NGF étant administré au sujet par voie intranasale.